Colorectal cancer spread at distance, RAS BRAF wild type pretreatted research hub

Randomized phase II study of PAnitumumab REchallenge followed by REgorafenib versus the reverse sequence in RAS and BRAF wild-type chemorefractory metastatic colorectal cancer patients. The PARERE trial

This study looks at treating advanced bowel cancer that has spread, using two different medicines. We want to see if giving one medicine first then the other, or vice versa, helps people live longer and has fewer side effects. It's for people whose cancer has specific genetic markers.